TEM Stock Dips As Tempus AI Bets $1.5B On Personalis

Tempus AI Inc. stocks have been trading up by 23.52 percent after upbeat coverage of its AI-driven healthcare platform.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TEM

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Tempus AI agreed to buy Personalis for about $1.5B, or $16.25 per PSNL share, mainly in stock with an option to use up to 50% cash.
The Personalis deal is meant to plug leading tumor-informed MRD tests into Tempus AI’s precision oncology and AI data platform, aiming at a roughly $20B MRD market.
TEM shares dropped roughly 4%–7% around the announcement, despite the offer giving Personalis holders about a 28% premium.
A shareholder-rights firm is reviewing the Personalis transaction for conflicts and fairness given Tempus AI’s prior stake and strategic ties.
Separately, Tempus AI beat Q2 revenue expectations, raised guidance to about $1.6B, expanded gross margin to 64%, and turned profitable, though TEM still trades well below 2025 highs.

Live Update At 12:33:22 EDT: On Wednesday, August 19, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 23.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TEM has been on a sharp upswing on the chart. Over the last few weeks, Tempus AI climbed from the low $40s to around $60.97 by 2026/08/19, with several strong range days in the $50–$55 zone. That’s a big momentum shift and tells traders money is rotating back into the TEM story.

Intraday, TEM is trading like a true momentum stock. The 5‑minute chart shows an early spike from the mid‑$50s toward $59, a hard pullback to the mid‑$50s, and then a grind higher to the low $61s. That pattern — morning volatility, mid‑day consolidation, afternoon push — is classic for liquid, news-driven names.

Fundamentals are starting to match that tape. Tempus AI just posted quarterly revenue of about $382.5M and has guided full-year sales to roughly $1.6B. Gross margin sits at a hefty 64% and overall gross margin around 73.5%, which is high for a diagnostics and data platform. TEM even printed positive net income of about $5.6M and positive EPS of $0.03, while free cash flow is still slightly negative.

More Breaking News

Balance sheet-wise, Tempus AI holds roughly $816M in cash and short-term investments, a current ratio of 3.3, and total debt to equity around 0.61. For traders, that combination — strong growth, improving profitability, and a solid cash cushion — creates a backdrop where news catalysts can move TEM fast in both directions.

Why Traders Are Watching TEM After The Personalis Deal

Traders are glued to TEM because Tempus AI just made a huge swing: a $1.5B move to acquire Personalis. The company is paying $16.25 per PSNL share, largely in stock, with an option to fund up to half the deal in cash. On paper, Tempus AI is buying a leading minimal residual disease (MRD) player to bolt onto its AI-enabled precision oncology platform.

The strategic idea is simple but big. MRD testing helps doctors see tiny traces of cancer that remain after treatment. By adding Personalis’s tumor-informed MRD assays, Tempus AI wants TEM to cover the full cancer care loop — diagnosis, treatment selection, and recurrence monitoring — across a roughly $20B MRD market. That fits the core TEM pitch: use massive data, genomics, and AI to guide care in real time.

The market did not cheer right away. TEM dropped more than 4% premarket and nearly 7% intraday on the deal headlines. Traders read that as concern over dilution, rich valuation, and integration risk. Needham highlighted that the deal values Personalis at roughly 15.5x estimated 2027 EV/sales, well above most small- and mid-cap growth peers. But the firm also argued the multiple lines up with Personalis’s MRD growth prospects and recent Medicare reimbursement wins, and it sees little antitrust risk given both firms’ modest share.

There’s also governance noise. A shareholder-rights firm is reviewing the Personalis buyout, pointing to Tempus AI’s existing stake and strategic relationship as potential conflicts. That may not stop the transaction, which is targeted to close in late 2026 or early 2027, but it adds headline risk that TEM traders must watch closely.

All of this is happening while Tempus AI is being framed as a major AI–healthcare infrastructure name, with hundreds of petabytes of clinical and genomic data from tens of millions of patients. For momentum traders, that “data moat” narrative plus a bold acquisition makes TEM a classic catalyst stock — one where sentiment can flip fast on any new headline.

Conclusion

Put it all together and TEM is a tug-of-war between execution and expectation. On one side, Tempus AI is finally showing the numbers many growth traders want to see: Q2 revenue modestly ahead of estimates, full-year guidance raised to around $1.6B, gross margin up to 64%, and a clean swing into positive net income. The balance sheet carries ample cash, and TEM’s core business — AI-driven precision oncology and data licensing — still leans into one of the market’s hottest themes.

On the other side, the Personalis acquisition keeps pressure on the stock. Traders see a $1.5B price tag, a premium near 28%, and a valuation around 15.5x projected 2027 sales. That combo raises fair questions about dilution, integration, and whether Tempus AI is moving too fast on M&A just as it reaches profitability. The governance review from a shareholder-rights firm only adds another layer of uncertainty, even if it never blocks the deal.

For active traders, the takeaway is to respect the volatility around TEM. The daily chart shows a strong uptrend off the lows, but every new headline on Personalis, MRD adoption, or guidance will matter. This content is for educational and research purposes only, but the trading mindset still applies. As Tim Sykes likes to remind his students, “The market doesn’t care about your opinion — it cares about catalysts and price action. Study the news, study the chart, and always be ready to cut losses fast.” And beyond reading the news and watching the chart, disciplined trade review is critical. As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!